Verici Dx (LSE:VRCI) ROCE % : -107.06% (As of Jun. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Verici Dx ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Verici Dx's annualized ROCE % for the quarter that ended in Jun. 2023 was -107.06%.

Verici Dx ROCE % Historical Data

The historical data trend for Verici Dx's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verici Dx ROCE % Chart

Verici Dx Annual Data

Trend

Dec20

Dec21

Dec22

ROCE %

-53.05

-99.02

Verici Dx Semi-Annual Data
	Jun21	Dec21	Jun22	Dec22	Jun23
ROCE %	-32.99	-77.68	-76.16	-80.56	-107.06

Verici Dx ROCE % Calculation

Verici Dx's annualized ROCE % for the fiscal year that ended in Dec. 2022 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	-9.361	/	( ( (10.369 - 1.357)	+	(11.744 - 1.849) )	/ 2 )
	=	-9.361	/	( (9.012	+	9.895)	/ 2 )
	=	-9.361	/	9.4535
	=	-99.02 %

Verici Dx's ROCE % of for the quarter that ended in Jun. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2023 )		(Q: Dec. 2022 )		(Q: Jun. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2023 )		(Q: Dec. 2022 )		(Q: Jun. 2023 )
	=	-8.328	/	( ( (11.744 - 1.849)	+	(7.408 - 1.745) )	/ 2 )
	=	-8.328	/	( ( 9.895	+	5.663 )	/ 2 )
	=	-8.328	/	7.779
	=	-107.06 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2023) EBIT data.

Verici Dx (LSE:VRCI) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Verici Dx ROCE % Related Terms

Thank you for viewing the detailed overview of Verici Dx's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Verici Dx (LSE:VRCI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Verici Dx PLC (LSE:VRCI) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

VRCDF:USA

Address

19 Stanwell Road, Avon House, Penarth, Cardiff, GBR, CF64 2EZ

Website

https://www.vericidx.com

Verici Dx PLC is an immuno-diagnostics development company. The company is focused on developing diagnostics technologies which will help understand the outcomes of an organ transplant surgery. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; and Tuteva, a post-transplant diagnostic focused upon acute cellular rejection including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels. The business of the Group comprises a single activity, that of the development of prognostic and diagnostic tests for kidney transplant patients.

Verici Dx (LSE:VRCI) Headlines

No Headlines